Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624329 | 0.93 | CTSL (0.52) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624321 | 0.92 | CTSL (0.57) | CTSLCTSKCTSBALDH1A1ALOX15 | |
| SCHEMBL13624330 | 0.88 | CTSL (0.56) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624334 | 0.85 | CTSL (0.51) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL4370766 | 0.85 | CTSL (0.46) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL4368350 | 0.84 | CTSL (0.45) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624345 | 0.84 | CTSL (0.45) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624358 | 0.83 | CTSL (0.52) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624172 | 0.82 | TAS1R3 (0.47) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624326 | 0.82 | CTSL (0.46) | CTSLCTSKALDH1A1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSL 24/4885CTSS 5/4885CTSK 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.